[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-349552-105":3,"detail-sidebar-cat-0-en-105":85,"doc-detail-349552-en":135},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":78,"head_meta":80,"extra_data":82,"updated_unix":84},105,"en","performance-and-clinical-benefit-of-comprehensive-genomic-profiling-of-gi-tumors-in-a-comprehensive-cancer-center-abstract","Performance and Clinical Benefit of Comprehensive Genomic Profiling of GI Tumors in a Comprehensive Cancer Center - Abstract","","Comprehensive genomic profiling (CGP) is increasingly used for GI cancers, yet its real-world applicability, performance, and clinical utility remain unclear. A retrospective evaluation assessed CGP success and clinical benefit in consecutive GI-tumor patients, including detection of actionable molecular targets. Among 1,450 samples, 9.7% were inadequate, mainly from low tumor DNA quantity. Actionable alterations were found in 28.1% of metastatic patients and targeted treatment improved survival.",{"@graph":14,"@context":77},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/performance-and-clinical-benefit-of-comprehensive-genomic-profiling-of-gi-tumors-in-a-comprehensive-cancer-center-abstract/349552/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/performance-and-clinical-benefit-of-comprehensive-genomic-profiling-of-gi-tumors-in-a-comprehensive-cancer-center-abstract/349552.png","ImageObject",300,407,{"name":42,"@type":43},"OmBimo","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-01","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",13,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69,73],{"name":60,"@type":61,"acceptedAnswer":62},"What was the main purpose of the study?","Question",{"text":63,"@type":64},"To determine the applicability, performance, and clinical benefit of comprehensive genomic profiling (CGP) in a real-world setting for GI cancer patients.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was CGP performance evaluated?",{"text":68,"@type":64},"CGP success and clinical benefit were assessed retrospectively in consecutive GI-tumor patients, focusing on detection of actionable molecular targets and comparison with routine diagnostics.",{"name":70,"@type":61,"acceptedAnswer":71},"What were the key results on sample adequacy and actionable alterations?",{"text":72,"@type":64},"Of 1,450 samples, 9.7% were inadequate for CGP, mainly due to low extracted tumor DNA quantity. Actionable genomic alterations were detected in 28.1% of metastatic cases.",{"name":74,"@type":61,"acceptedAnswer":75},"Did targeted therapy based on CGP improve survival?",{"text":76,"@type":64},"Yes. Survival was longer for patients who received treatment for actionable genomic alterations, and this advantage was confirmed in an exploratory analysis (adjusted hazard ratio 0.72, P 5 .002).","https://schema.org",{"og:url":32,"og:type":79,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":81,"canonical":32},"index,follow",{"doc_id":83,"site_id":7},349552,1790537691,{"code":4,"msg":86,"data":87},"success",[88,92,96,100,105,110,115,119,124,127,131],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Exam",70,"exam",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},5,"Comic",60,"comic",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},6,"Technology",50,"technology",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},7,"Healthcare",40,"healthcare",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":117,"slug":118},8,30,"research-report",{"id":120,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":122,"slug":123},9,"Religion & Spirituality",20,"religion-spirituality",{"id":122,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":122,"slug":126},"World Cup","world-cup",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":128,"slug":130},10,"Lifestyle","lifestyle",{"id":132,"doc_module":4,"doc_module_name":25,"category_name":133,"show_sort_weight":101,"slug":134},19,"General","general",{"code":4,"msg":86,"data":136},{"doc_id":83,"user_id":137,"nickname":42,"user_avatar":138,"doc_module":4,"category_id":116,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":139,"file_id":140,"file_url":141,"file_type":142,"file_size":143,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":144,"language":145,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":146,"faqs":147,"seo_title":148,"seo_description":12,"update_tm":149,"read_time":150,"preview_page_count":33,"preview_urls":151},962090893581,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Original Reports | Precision Medicine  \nPerformance and Clinical Beneﬁt of Comprehensive Genomic Proﬁling of GI Tumors in a Comprehensive Cancer Center  \nGiulia Maddalena, MD, PhD1  ; Valentina Angerilli, MD2; Federico Nichetti, MD1  ; Gianmarco Ricagno, MD1,3  ; Jessica Gasparello, PhD4  ; Elena Mattiuzzo, PhD1; Maria Caterina De Grandis, MD1; Elena Carcea, PhD1; Carlotta Ceccon, PhD2,3  ; Anna Roma, MD5;  \nEleonora Perissinotto, MD1,3; Sara Sperotto, MD1,3  ; Giacomo Di Paolo, MD1,3; Marta Sbaraglia, MD4; Marco Maruzzo, MD, PhD5  ; Francesca Bergamo, MD1  ; Angelo Paolo Dei Tos, MD4; Matteo Fassan, MD, PhD4,6  ; and Sara Lonardi, MD1   \nDOI [https://doi.org/10.1200/PO-25-01](https://doi.org/10.1200/PO-25-01)168  \n\n| ABSTRACT |  |\n| --- | --- |\n| PURPOSE | Comprehensive genomic proﬁling (CGP) is increasingly adopted in the management of patients affected by GI cancers. However, the applicability, performance, and clinical utility ofCGP in the real-world setting are still undeﬁned. |\n| METHODS | We retrospectively evaluated CGP performance and clinical beneﬁt in consecutive patients with GI tumor at the Veneto Institute of Oncology-IRCCS, Padua. We assessed CGP success and its advantage over routine diagnostics in detecting actionable molecular targets. A custom list of gain alterations was deﬁned, including targets not classiﬁed as ESMO Scale for Clinical Actionability of molecular Targets tier IA at the time of analysis. |\n| RESULTS | Of the 1,450 samples, 140 (9.7%) were inadequate for CGP. Failure was mainly due to low quantity of extracted tumor DNA (P 5 .002) . Of the 1,265 metastatic patients, GAs were detected in 355 (28.1%) cases, of whom 55 (15.5%) were treated with targeted therapy. Survival did not differ between patients with no GAs and those with GAs who were not treated accordingly (median overall survival 12.0 v 10.9 months), whereas it was signiﬁcantly longer for those receiving treatment for actionable GAs (26.4 months) . This advantage was conﬁrmed in an exploratory, inverse probability of treatment-weighted analysis (adjusted hazard ratio, 0.72 [95% CI, 0.58 to 0.89]; P 5 .002) . Among 283 (83.7%) untreated patients with complete follow-up, 41.6% did not receive targeted therapy due to lack of clinical trial or failure to meet inclusion criteria. |\n| CONCLUSION | Appropriate specimen selection and early molecular assessment at the time of advanced disease diagnosis are essential to detect clinically actionable molecular alterations and therapeutic opportunities in patients with GI cancers. Our results support CGP in comprehensive cancer centers. |\n\nACCOMPANYING CONTENT  \n Data Supplement  \nAccepted July 1, 2026  \nPublished August 12, 2026  \nJCO Precis Oncol 10:e2501168 © 2026 by American Society of Clinical Oncology  \nCreative Commons Attribution Non-Commercial No Derivatives 4.0 License  \nINTRODUCTION  \nNext-generation sequencing (NGS) of tumor samples is a crucial tool in the shift from a one-size-ﬁts-all paradigm toa tailored therapeutic decision making. In 2018, the ESMO Precision Medicine Working Group deﬁned the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)1 and drafted the ﬁrst guidelines to endorse the use of multigene, panel-based NGS in different malignancies to guide treatment with matching drugs.2 Overtime, since the sensitivity of detecting alterations is directly related to sequence coverage, comprehensive genomic proﬁling (CGP, approximately 300-500 genes) panels have been progressively preferred over limited (approximately 10-50 genes) ones.2-5 From these, clinicians may identify novel actionable  \nmolecular targets to increase treatment opportunities with tailored anticancer drugs within clinical trials or with offlabel access programs, with the ﬁnal goal to pursue precision oncology.6  \nNonetheless, data on applicability, performance, and impact of CGP beyond standard clinical practice in the real-world setting are limited. About the technique, a number of caveats migh","cbCaif5HiwMqDhhc","https://ap.wps.com/l/cbCaif5HiwMqDhhc","pdf",2530204,11,"English","# Abstract\n## Purpose\n## Methods\n## Results\n## Conclusion\n# Introduction and Context\n## Key Objective\n## Knowledge Generated\n## Relevance","[{\"question\":\"What was the main purpose of the study?\",\"answer\":\"To determine the applicability, performance, and clinical benefit of comprehensive genomic profiling (CGP) in a real-world setting for GI cancer patients.\"},{\"question\":\"How was CGP performance evaluated?\",\"answer\":\"CGP success and clinical benefit were assessed retrospectively in consecutive GI-tumor patients, focusing on detection of actionable molecular targets and comparison with routine diagnostics.\"},{\"question\":\"What were the key results on sample adequacy and actionable alterations?\",\"answer\":\"Of 1,450 samples, 9.7% were inadequate for CGP, mainly due to low extracted tumor DNA quantity. Actionable genomic alterations were detected in 28.1% of metastatic cases.\"},{\"question\":\"Did targeted therapy based on CGP improve survival?\",\"answer\":\"Yes. Survival was longer for patients who received treatment for actionable genomic alterations, and this advantage was confirmed in an exploratory analysis (adjusted hazard ratio 0.72, P 5 .002).\"}]","Performance and Clinical Benefit of Comprehensive Genomic Profiling of GI Tumors in a Comprehensive Cancer Center - Abstract | PDF",1790084299,28,[152,156,160,164],{"page_no":22,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5a32dcc70b0589494768ef7383551942.webp",983,1315,{"page_no":26,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/99d1abb1452339a80af3c71304726ae7.webp",982,1314,{"page_no":30,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9907b7b514eac6cf9a736d9aa93cc7cc.webp",981,1312,{"page_no":33,"url":165,"width":166,"height":167},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4d6045393a3efe03306ca3ec4f46f3ca.webp",980,1311]